Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne [Phase 3]

View source ↗

Summary

Phase 3 clinical trial results evaluating the safety and efficacy of Tazarotene Foam 0.1% for facial acne have been posted. The study enrolled subjects with acn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acne Vulgaris

Drugs mentioned

• tazarotene foam (tazarotene)

Snippet

Sponsor: Stiefel, a GSK Company | Conditions: Acne Vulgaris | Phase 3 | Status: COMPLETED | Results posted: 2012-07-06